335 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22690 | After standard therapy / RECIST 1.1 | Christiane Jungels | Multiple | Transgene S.A. | TG6002.02 | Trial closed | A Phase I/IIa study of TG6002 (VV TK-RR-FCU1) administered by intravenous (IV) infusions in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors | christiane.jungels@hubruxelles.be | 1/2a | 1 | |
| 22677 | - prior anti-myeloma treatment included both a PI- and lenalidomide-containing regimens - no previous therapy with Pomalidomide nor CD-38 MoAb |
Nathalie Meuleman | Myeloma | EMN | The APOLLO Study | Trial closed for recruitment | A phase III Study comparing Pomalidomide and Dexamethasone with or without Daratumumab in Subjects with Relapsed or Refractory Multiple Myeloma who have received at least one prior line of therapy with both Lenalidomide and a Proteasome Inhibitor | nathalie.meuleman@hubruxelles.be | 3 | 3 | |
| 22635 | relapsed or refractory AML / MDS with R-IPSS ? 2 with failure to prior treatment/ not eligible for standard of care therapy | Ahmad Hussein Awada | Multiple | Celyad | THINK | Trial closed | A multinational, open-label, dose escalation Phase I/II study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types | ahmad.awada@hubruxelles.be | 1/2 | 1 | |
| 29425 | Progression on last line of treatment, no other therapeutic option | Nathalie Meuleman | Myeloma | iTeos | TIG-007 | Trial open for recruitment | Study of EOS884448 alone, and in combination with iberdomide with or without dexamethasone, in participants with relapse or refractory multiple myeloma (TIG-007) | nathalie.meuleman@hubruxelles.be | 1/2 | 1 | |
| 29407 | Spyridon Sideris | Kidney | AVEO PHARMACEUTICALS, INC. | TiNivo-2 | Trial closed for recruitment | A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor | spyridon.sideris@hubruxelles.be | 3 | 3 | ||
| 29191 | Nuria Kotecki | Multiple | T-Knife GmbH | TK-SCR-01 | Trial closed | Assessing Frequency of HLA-Genotypes and Tumor Antigen Expression in Subjects with Relapsed/Refractory, Advanced-Stage Solid Tumors that may Qualify for Novel T Cell Receptor Based Therapies | Nuria.Kotecki@hubruxelles.be | ||||
| 22674 | CD30 positive Peripheral T-cell Lymphoma/Ann Arbor stage I-IV/at least 1 measurable lesion >=1,5cm | Marie Maerevoet | Non-Hodgkin lymphoma | Lysarc | TOTAL | Trial closed | A phase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenance (TOTAL) | marie.maerevoet@hubruxelles.be | 2 | 2 | |
| 22706 | ER+/HER2+. cT1-3. N0-1. >1 cm. Neoadjuvant. Age >65 years old | Andrea Gombos | Breast | IBCSG | TOUCH | Trial closed | Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer (IBCSG 55-17 / TOUCH) | accueil.oncologie@hubruxelles.be | 2 | 2 | |
| 29331 | Andrea Gombos | Breast | AstraZeneca | TROPION-Breast01 | Trial closed for recruitment | A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy | accueil.oncologie@hubruxelles.be | 3 | 3 | ||
| 29372 | Andrea Gombos | Breast | AstraZeneca | TROPION-Breast02 | Trial open for recruitment | A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02) | accueil.oncologie@hubruxelles.be | 3 | 3 | ||
| 29674 | Michail Ignatiadis | Breast | AstraZeneca | TROPION-Breast03 | Trial open for recruitment | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03) | michail.ignatiadis@hubruxelles.be | 3 | 3 | ||
| 22665 | HER2 positive/ RECIST 1.1/ After HER2 targeting treatment | Philippe Aftimos | Breast | Synthon Biopharmaceuticals | TULIP | Trial closed | A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer / TULIP | philippe.aftimos@hubruxelles.be | 3 | 3 | |
| 22658 | Second line metastatic, biopsy | Yassine Lalami | Bones - soft tissue | EORTC | UPSTREAM | Trial closed | A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck "UPSTREAM" | yassine.lalami@hubruxelles.be | 2 | 2 | |
| 22670 | Progressive. At least 1 line of athracycline and/or taxane | Daphné t'Kint de Roodenbeke | Breast | AstraZeneca | VIOLETTE | Trial closed | A Phase II, Open Label, randomized, Multi-center Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR-Related Genes (including BRCA 1/2) (VIOLETTE) | daphne.tkint@hubruxelles.be | 2 | 2 |